PharmiNews

The Directory of Pharma Companies and News

Biotie

Biotie logo
Biotie is a specialized drug development company focused on products for neurodegenerative and psychiatric disorders. Biotie's development has delivered Selincro (nalmefene) for alcohol dependence, which received European marketing authorization in 2013 and is currently being rolled out across Europe by partner Lundbeck. The current development products include tozadenant for Parkinson's disease, which is in Phase 3 development, and two additional compounds which are in Phase 2 development for cognitive disorders including Parkinson's disease dementia, and primary sclerosing cholangitis (PSC), a rare fibrotic disease of the liver.
Category:
Category:

Biotie News

DateNews
2016-08-25THE LISTING COMMITTEE OF NASDAQ HELSINKI HAS RESOLVED TO DELIST THE SHARES OF BIOTIE THERAPIES CORP.
2016-08-18BIOTIE THERAPIES CORP. APPLIES FOR DELISTING OF ITS SHARES FROM NASDAQ HELSINKI
2016-05-18BIOTIE TO DELIST ITS ADS FROM THE NASDAQ GLOBAL SELECT MARKET
2016-05-18BIOTIE CANCELS ALL TREASURY SHARES HELD BY THE COMPANY
2016-03-22Biotie's Financial Statement Report and Corporate Governance Statement 2015 published
2016-03-18Biotie Financial Statement Release 2015
2016-03-04CHANGE IN THE TIME OF BIOTIE THERAPIES' ANNUAL GENERAL MEETING 2016
2016-01-19CORDA ANNOUNCES A RECOMMENDED CASH TENDER OFFER FOR ALL SHARES, ADSs AND OTHER EQUITY INSTRUMENTS IN BIOTIE
2016-01-05The Board of Directors of Biotie Therapies Corp. has Approved Two Year Incentive Plan for Employees
2015-12-14Biotie Therapies Oyj :Disclosure under Chapter 9, Section 5 of the Finnish Securities Markets Act
2015-06-17Notification according to Chapter 9, Section 5 of the Finnish Securities Markets Act
2015-06-16Biotie Publishes Listing Prospectus in Finland
2015-06-16Biotie Announces Closing of U.S. Public Offering and Conversion of Convertible Notes
2015-06-12Biotie Announces Exercise of Over-allotment Option
2015-06-12Change in the number of votes relating to Biotie Therapies Corp.'s shares
2015-06-11Biotie Announces Completion of Pricing of U.S. Public Offering of ADSs and Conversion of Convertible Notes
2015-06-08CORRECTION: Biotie Increases Proposed U.S. Public Offering of ADSs
2015-06-08Biotie Increases Proposed U.S. Public Offering of ADSs
2015-06-04Biotie Commences Proposed U.S. Public Offering of ADSs
2015-05-29Organization of the Board of Directors and Board committees
2015-05-29Biotie completes the issuance of convertible notes and warrants
2015-05-26Change in Biotie Therapies' Financial Calendar 2015
2015-05-26RESOLUTIONS OF THE ANNUAL GENERAL MEETING OF BIOTIE THERAPIES CORP. AND ORGANIZATION OF THE BOARD
2015-05-25Biotie announces agreement with FDA on a Special Protocol Assessment for tozadenant Phase 3 study
2015-05-14Biotie Has Filed Registration Statement for U.S. Public Offering
2015-05-07Biotie announces irrevocable subscription undertakings for Convertible Notes from existing shareholders and amends propo...
2015-05-06Biotie interim report 1 January - 31 March 2015
2015-04-23INVITATION TO THE ANNUAL GENERAL MEETING OF BIOTIE THERAPIES CORP.
2015-04-23Biotie proposes to strengthen its capital structure by approximately EUR 95 million through a directed issue of converti...
2015-04-23Biotie provides update on tozadenant Phase 3 program
2015-03-31Biotie announces start of patient enrolment into Phase 2a clinical study with BTT1023 in primary sclerosing cholangitis
2015-03-20Change in Biotie Therapies' Annual General Meeting 2015
2015-03-09Correction: Biotie's Financial Statement Report and Corporate Governance Statement 2014 published
2015-03-09Biotie's Financial Statement Report and Corporate Governance Statement 2014 published
2015-02-27Biotie Financial Statement Release 2014
2015-02-27Biotie updates outlook - completion of annual impairment review
2015-02-20Biotie provides portfolio update on tozadenant
2015-02-17Biotie: BTT1023 receives positive opinion for Orphan Drug Designation from COMP
2015-01-30Biotie announces top-line results from nepicastat (SYN117) study in cocaine dependence
2014-12-23BIOTIE ANNOUNCES START OF SYN120 PHASE 2A TRIAL IN PARKINSON'S DISEASE DEMENTIA AND PROVIDES OUTLOOK UPDATE FOR NEAR TER...
2014-12-23Biotie: new treasury shares and cancellation of shares registered with the Trade Register
2014-12-17Issue of new treasury shares of Biotie Therapies Corp without consideration and cancellation of shares held by Biotie Th...
2014-11-26BIOTIE: UK'S NICE ISSUES POSITIVE FINAL GUIDANCE FOR SELINCRO®
2014-10-31Biotie interim report 1 January - 30 September 2014
2014-09-29Biotie's Financial Information in 2015
2014-09-19Biotie: Selincro enters the market in France
2014-08-29Biotie: Selincro enters the market in Germany
2014-08-28Biotie: Formal transfer of global rights for tozadenant to Biotie concluded
2014-08-01Correction to Biotie Therapies Corp. interim report for January - June 2014
2014-08-01Correction to Stock Exchange Release: Change in the number of votes relating to Biotie Therapies Corp.'s shares publishe...
2014-07-30Biotie interim report 1 January - 30 June 2014
2014-07-30Biotie updates outlook on tozadenant and SYN120
2014-07-24Clinical study with Biotie's BTT1023 in primary sclerosing cholangitis awarded external grant funding
2014-07-22Biotie: Selincro enters the market in Spain
2014-07-11Biotie decides not to exercise option to acquire Neurelis, Inc. but retains economic interest in future success of NRL-1
2014-07-10Biotie: Selincro receives positive draft guidance from UK's NICE
2014-07-08Biotie: Tozadenant Phase 2b Parkinson's disease study published in Lancet Neurology
2014-07-08Biotie awarded USD 2 million grant from The Michael J. Fox Foundation for a clinical study with SYN120 in Parkinson's Di...
2014-05-27Biotie: nepicastat study in cocaine dependence completes enrollment ahead of schedule - top-line data expected around en...
2014-05-09Biotie: Change in the number of votes
2014-05-09Biotie interim report 1 January - 31 March 2014
2014-03-21Biotie to regain global rights to tozadenant from UCB
2014-03-04Biotie's Financial Statement Report and Corporate Governance Statement 2013 published
2014-02-28Biotie Financial Statement Release 2013
2014-02-28Biotie updates outlook: Intends to develop SYN120 internally and will not exercise its option to acquire Neurelis until ...
2014-01-08New Treasury Shares of Biotie Therapies Corp registered with the Trade Register
2014-01-03The Board of Directors of Biotie Therapies Corp. has Approved Three Year Incentive Plans for Employees
2014-01-03Issue of new treasury shares of Biotie Therapies Corp without consideration
2013-11-21Biotie's loan obligations to Tekes reduced by EUR 2.8 million
2013-11-14Biotie: Notification according to Chapter 9, Section 10 of the Finnish Securities Market Act
2013-11-01Biotie interim report 1 January - 30 September 2013
2013-10-31Biotie: Lundbeck and Otsuka announce partnership to develop and commercialize nalmefene in Japan
2013-10-07Biotie's Financial Information in 2014
2013-09-26Biotie: Selincro enters the market in Italy
2013-09-24Biotie Completes Planned Portfolio Review
2013-08-02Biotie interim report 1 January - 30 June 2013
2013-06-04Biotie purchases option to acquire Neurelis, Inc.
2013-05-10Biotie announces start of clinical study with nepicastat (SYN117) in cocaine dependence
2013-05-06Biotie: Selincro launched in the United Kingdom
2013-05-03Biotie interim report 1 January - 31 March 2013
2013-04-22Biotie: Selincro launched in first European markets
2013-03-21Biotie Presents Tozadenant Phase 2b data at AAN Annual Meeting
2013-03-07Biotie's Annual Financial Report and Corporate Governance Statement 2012 published
2013-02-28Biotie: Selincro (nalmefene) receives European marketing authorization
2013-02-28Biotie financial statement report 1 January - 31 December 2012
2013-02-28Biotie updates outlook - non-cash impairment charge for ronomilast
2013-02-27Amendment to the release on UCB license of worldwide rights to tozadenant in Parkinson's disease from Biotie
2013-02-26Biotie: UCB to license worldwide rights to tozadenant in Parkinson's disease from Biotie
2013-01-02David Cook appointed Chief Financial Officer of Biotie
2012-12-27Biotie reports top-line data from clinical study with nepicastat (SYN117) in post-traumatic stress disorder
2012-12-14Biotie: Selincro(TM) (nalmefene) receives positive opinion for approval in the European Union
2012-12-11Biotie's tozadenant (SYN115) meets primary and multiple secondary endpoints in phase 2b study in Parkinson's disease
2012-11-02Biotie Interim report 1 January - 30 September 2012
2012-11-02Biotie's Financial Information in 2013
2012-09-17Change in Biotie management
2012-09-17New Biotie shares and increase of share capital registered with the Finnish Trade Register
2012-09-07Notification according to Chapter 2, Section 10 of the Finnish Securities Market Act
2012-09-07A listing prospectus concerning listing of new shares in Biotie has been published
2012-09-07Biotie has completed a directed share issue of EUR 20 million to institutional and strategic investors
2012-09-07Lundbeck has made EUR 10 Million equity investment in Biotie and the parties amend the Selincro licensing agreement rega...
2012-08-03Biotie Interim report 1 January - 30 June 2012
2012-08-03Biotie renews SEDA agreement with YA Global, securing committed standby equity of up to 20 million euro
2012-07-05Biotie Completes Enrollment in Phase 2b Trial of Tozadenant in Parkinson's Disease
2012-06-26Biotie announces Roche has decided to not exercise its rights to SYN120, a novel 5-HT6 antagonist for cognitive disorder...
2012-05-04Biotie Interim report 1 January - 31 March 2012
2012-05-02Change in the Board of Directors
2012-04-24Biotie and Seikagaku agree to end License Agreement on Biotie's VAP-1 antibody program
2012-03-08Biotie's Stock Exchange Releases published in 2011
2012-03-08Biotie's Annual Financial Report and Corporate Governance Statement 2011 published
2012-03-05Data presented at the 2012 European Congress of Psychiatry showing that Selincro(TM) reduces total alcohol consumption b...
2012-03-01Biotie Successfully Completes Imaging Study with SYN120
2012-02-24Biotie Therapies Corp. financial statement release 1 January - 31 December 2011
2012-02-13Panu Miettinen appointed Chief Financial Officer of Biotie
2011-12-21Biotie's partner Lundbeck submits European Marketing Authorization Application for Selincro(TM) (nalmefene)
2011-12-13US National Institute on Drug Abuse (NIDA) to Conduct Clinical Study on Biotie's Nepicastat in Cocaine Dependence
2011-12-07The Board of Directors of Biotie Therapies Corp. Decided on Incentive Plans for Employees
2011-11-28Biotie's loan obligations to Tekes reduced by EUR 2.2 million
2011-11-23Biotie provides UCB partnership update on SYN118
2011-11-04Biotie's Financial Information in 2012
2011-11-04Biotie Therapies Corp. Interim report 1 January - 30 September 2011
2011-11-04Biotie Updates Outlook - Non-cash Impairment Charge for SYN118
2011-10-28Biotie Terminates the Agreement to Acquire Newron
2011-10-21Biotie informed that Merck Serono is returning full global rights for safinamide to Newron
2011-10-05Notice to Biotie shareholders on registration of merger plan and documents available for review
2011-09-27Biotie to Acquire Newron Creating a Leading European Biopharmaceutical Company Focused on Central Nervous System Drug De...
2011-09-01New interim CFO in Biotie
2011-08-05Biotie Therapies Corp. Interim report 1 January - 30 June 2011
2011-07-28Correction to Biotie Therapies Corp. interim report for January - March 2011
2011-07-26Notification according to Chapter 2, Section 10 of the Finnish Securities Market Act regarding changes in number of vote...
2011-07-25Biotie Advances Clinical Program for SYN120 with Imaging Study at Johns Hopkins Center of Excellence
2011-06-15Biotie Announces Completion of Phase 3 Program with Nalmefene in Alcohol Dependence; European Marketing Authorization Ap...
2011-05-24Biotie announces topline data from an exploratory phase 2a study with SYN118 in Parkinson's disease
2011-05-13Biotie Therapies Corp. interim report 1 January - 31 March 2011
2011-05-06RESOLUTIONS OF THE ANNUAL GENERAL MEETING OF BIOTIE THERAPIES CORP.
2011-04-07Biotie announces start of Phase 2b trial of SYN115 in Parkinson's disease
-0001-11-30Biotie announces start of tozadenant Phase 3 Study in Parkinson's disease
-0001-11-30Biotie interim report 1 January - 30 June 2015
-0001-11-30Biotie to Present at the upcoming Stifel 2015 Healthcare Conference
-0001-11-30Biotie interim report 1 January - 30 September 2015
-0001-11-30Biotie's financial information in 2016
-0001-11-30Disclosure under Chapter 9, Section 5 of the Finnish Securities Markets Act
-0001-11-30Biotie:Issuance of shares pursuant to option and equity incentive plans
-0001-11-30CORRECTION ANNOUNCEMENT: ACORDA ANNOUNCES A RECOMMENDED CASH TENDER OFFER FOR ALL SHARES, ADSs AND OTHER EQUITY INSTRUME...
-0001-11-30U.S. antitrust regulation waiting period relating to tender offer has expired
-0001-11-30ACORDA HAS FILED THE DRAFT TENDER OFFER DOCUMENT RELATING TO ITS PUBLIC TENDER OFFER FOR BIOTIE THERAPIES WITH THE FINNI...
-0001-11-30STATEMENT OF THE BOARD OF DIRECTORS OF BIOTIE THERAPIES CORP. REGARDING THE VOLUNTARY PUBLIC TENDER OFFER BY ACORDA THER...
-0001-11-30THE FINNISH FINANCIAL SUPERVISORY AUTHORITY HAS APPROVED THE TENDER OFFER DOCUMENT, ACORDA WILL COMMENCE THE VOLUNTARY P...
-0001-11-30ACORDA SUPPLEMENTS THE TENDER OFFER DOCUMENT RELATING TO THE VOLUNTARY PUBLIC TENDER OFFER ON 18 MARCH 2016
-0001-11-30ACORDA SUPPLEMENTS THE TENDER OFFER DOCUMENT RELATING TO THE VOLUNTARY PUBLIC TENDER OFFER ON 22 MARCH 2016
-0001-11-30ACORDA ANNOUNCES PRELIMINARY TENDER OFFER RESULTS AND ACCEPTANCE OF THE SECURITIES IN BIOTIE TENDERED IN TENDER OFFER
-0001-11-30FINAL RESULTS OF ACORDA'S TENDER OFFER AND COMMENCEMENT OF A SUBSEQUENT OFFER PERIOD
-0001-11-30ACORDA THERAPEUTICS TO COMMENCE A COMPULSORY REDEMPTION PROCEEDING IN RESPECT OF THE REMAINING BIOTIE THERAPIES CORP. SH...
-0001-11-30FINAL RESULTS OF THE SUBSEQUENT OFFER PERIOD OF ACORDA'S TENDER OFFER FOR ALL SECURITIES IN BIOTIE
-0001-11-30Biotie Interim Report 1 January - 31 March 2016
-0001-11-30NORDEA BANK FINLAND PLC'S MARKET-MAKING FOR BIOTIE THERAPIES CORP.'S SHARE ENDS
-0001-11-30TRUSTEE APPOINTED FOR THE REDEMPTION PROCEEDINGS CONCERNING BIOTIE'S MINORITY SHARES
-0001-11-30BIOTIE ANNOUNCES THAT THE DELISTING OF ITS ADS HAS BECOME EFFECTIVE
-0001-11-30Change in Biotie Therapies' Financial Reporting Calendar 2016
-0001-11-30CHANGES IN THE MANAGEMENT TEAM
-0001-11-30ARBITRATORS APPOINTED FOR THE REDEMPTION PROCEEDINGS OF BIOTIE'S MINORITY SHARES
-0001-11-30Biotie Therapies Corp.'s Interim Report for the reporting period January 1 - June 30, 2016
-0001-11-30Biotie: BTT1023 receives Orphan Drug Designation in the United States
-0001-11-30ARBITRAL TRIBUNAL CONFIRMED ACORDA'S REDEMPTION RIGHT REGARDING BIOTIE SHARES AND BIOTIE SHARES TRADING HAS BEEN TERMINA...
-0001-11-30ACORDA GAINS TITLE TO BIOTIE SHARES AND THE SHARES WILL DELIST
Brought to you by PharmiWeb.com - Latest Jobs in Pharma
Brought to you by www.pharmiweb.com - Latest Jobs in Pharma.